Centaurus Financial’s NovoCure NVCR Stock Holding History

Centaurus Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,075	Closed	-$34K	–	1531
2018 Q2	$34K	Buy	+1,075	New	+$29.9K	﹤0.01%	1072

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Centaurus Financial's NVCR Position: Q3 2018 in Review

Centaurus Financial sold out of NovoCure (NVCR) in Q3 2018, closing a stake of 1,075 shares — an estimated $34K sold.

Centaurus Financial first reported a position in NVCR in Q2 2018 and held it in 1 quarter. The position peaked at $34K in Q2 2018. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

Centaurus Financial reported no remaining NovoCure position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 1,075 NovoCure shares in Q3 2018, an estimated $34K.
Centaurus Financial first reported a position in NovoCure in Q2 2018 and held it in 1 quarter.
Centaurus Financial's NovoCure position peaked at $34K in Q2 2018.
176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.